In recognition of Rare Disease Day, ProQR will hold a luncheon at the Company’s headquarters in Leiden,
“We fully support Rare Disease Day 2018, which will raise public awareness about rare diseases and bring attention to the importance of research to develop therapies for these patients who have no available treatment options,” said Daniel A. de Boer, Chief Executive Officer of ProQR. “With an estimated 7,000 rare diseases known today and with less than 400 available therapies available, there is a dire need to quickly develop and bring to patients the medicines they need. On this day, it is a privilege to pay tribute to Henri, a good friend and mentor and pioneer in rare diseases. We plan to honor his legacy through completing the mission that we set out on together.”
About Rare Disease Day
Rare Disease Day is a global campaign to raise awareness of rare diseases. Since its inception in 2008, led by EURORDIS-Rare Diseases Europe and its
About the late Henri A. Termer
Henri was ProQR’s co-founder, vice chairman and served on the Company’s supervisory board since
About Leber’s Congenital Amaurosis 10
Leber’s congenital amaurosis (LCA) is the most common cause of blindness due to genetic disease in children and consists of a group of diseases of which LCA 10 is the more severe forms. LCA 10 is caused by mutations in the CEP290 gene of which the p.Cys998X mutation is the most common. LCA 10 leads to early loss of vision causing most people to lose their sight in the first few years of life. To date, there are no treatments approved or other products in clinical development that treat the underlying cause of the disease. Approximately 2,000 people in the Western world have LCA 10 because of this mutation.
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such statements include those relating to Rare Disease Day 2018, and our clinical development and therapeutic potential of our product candidates. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the
Chief Financial Officer
T: +1 415 231 6431
Source: ProQR Therapeutics N.V.